Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2014/07010Aexternal-prioritypatent/TR201407010A2/en
Application filed by Arven Ilac Sanayi Ve Ticaret AsfiledCriticalArven Ilac Sanayi Ve Ticaret As
Publication of MA39289ApublicationCriticalpatent/MA39289A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
La présente invention se rapporte à une formulation pharmaceutique pour inhalation comprenant vilanterol en tant qu'agent actif, un excipient et du stéarate de magnésium dans le traitement et la prophylaxie des maladies respiratoires telles que l'asthme, la broncho-pneumopathie chronique obstructive (bpco), ainsi qu'à un procédé pour produire ce formulation.The present invention relates to a pharmaceutical formulation for inhalation comprising vilanterol as an active agent, an excipient and magnesium stearate in the treatment and prophylaxis of respiratory diseases such as asthma, chronic obstructive pulmonary disease (bpco ), as well as a process for producing this formulation.
MA039289A2014-06-162015-06-15Pharmaceutical formulations of vilanterol
MA39289A
(en)
compound, methods for activating soluble guanylate cyclase, for treating one or more conditions selected from a disease in a patient and for treating a disease or condition, pharmaceutical composition, use of a compound, and, medicament.
C38 UNDERSTANDING THERAPEUTICS IN IPF: Clinical Experience With Nintedanib For Idiopathic Pulmonary Fibrosis In 3 Uk Tertiary Interstitial Lung Disease Centres
The new indasol carboxamide The process of preparing such substances; pharmaceutical preparations which contain such substances And the use of such substances In drug production